Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Department of Surgery, Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Thromb Haemost. 2022 Mar;122(3):353-362. doi: 10.1055/a-1515-9529. Epub 2021 Jul 4.
Development of ascites is the most common form of decompensation of cirrhosis. We aimed to investigate the coagulation system in ascitic fluid and plasma of patients with cirrhosis. We determined coagulation parameters and performed clotting and fibrinolysis experiments in ascitic fluid and plasma of thoroughly characterized patients with cirrhosis and ascites ( = 25) and in plasma of patients with cirrhosis but without ascites ( = 25), matched for severity of portal hypertension. We also investigated plasma D-dimer levels in an independent cohort of patients ( = 317) with clinically significant portal hypertension (HVPG ≥ 10 mmHg), grouped according to ascites severity. Ascitic fluid was procoagulant in a clotting assay. The procoagulant potential of ascitic fluid was abolished by depletion of extracellular vesicles from ascitic fluid by filtration or by addition of a tissue factor-neutralizing antibody. Compared with plasma, extracellular vesicle-associated tissue factor activity was high in ascitic fluid, while activities of other coagulation factors were low. The extracellular vesicle-depleted fraction of ascitic fluid induced fibrinolysis, which was prevented by aprotinin, indicating the presence of plasmin in ascitic fluid. Plasma peak thrombin generation and parameters reflecting fibrinolysis were independently associated with the presence of ascites. Finally, plasma D-dimer levels were independently linked to ascites severity in our second cohort comprising 317 patients. In conclusion, coagulation and fibrinolysis become activated in ascites of patients with cirrhosis. While tissue factor-exposing extracellular vesicles in ascitic fluid seem unable to pass the peritoneal membrane, fibrinolytic enzymes get activated in ascitic fluid and may re-enter the systemic circulation and induce systemic fibrinolysis.
腹水形成是肝硬化失代偿最常见的形式。我们旨在研究肝硬化患者腹水中和血浆中的凝血系统。我们在充分特征描述的肝硬化伴腹水患者(n=25)的腹水中和血浆中以及无腹水的肝硬化患者(n=25)的血浆中测定了凝血参数,并进行了凝血和纤溶实验,这些患者的门静脉高压严重程度相匹配。我们还在具有临床显著门静脉高压(HVPG≥10mmHg)的独立患者队列(n=317)中调查了血浆 D-二聚体水平,根据腹水严重程度进行分组。在凝血测定中,腹水具有促凝作用。腹水通过过滤或添加组织因子中和抗体从腹水中外泌体耗竭,可消除腹水的促凝潜能。与血浆相比,腹水中外泌体相关的组织因子活性较高,而其他凝血因子的活性较低。富含外泌体的腹水 depleted fraction 可诱导纤溶,而 aprotinin 可阻止纤溶,表明腹水中存在纤溶酶。血浆最大凝血酶生成和反映纤溶的参数与腹水的存在独立相关。最后,在包含 317 名患者的第二个队列中,血浆 D-二聚体水平与腹水严重程度独立相关。总之,肝硬化患者的腹水会引发凝血和纤溶激活。尽管腹水中外泌体暴露的组织因子似乎无法穿过腹膜,但纤维蛋白溶解酶在腹水中被激活,并可能重新进入体循环并诱导全身性纤溶。